Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
1267.1%
Buyback spend (TTM)
N/A
Cumulative buybacks
$3.85M
Key takeaways
- Diluted share count is up 1267.1% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
Dividend & buyback yield over time for SELLAS Life Sciences Group (SLS)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for SELLAS Life Sciences Group (SLS)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for SELLAS Life Sciences Group (SLS)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for SELLAS Life Sciences Group (SLS)
Latest: $0.00
Overview
As of the 2025 fiscal year, SELLAS Life Sciences Group (SLS) reported buyback spend of $0.00.
SELLAS Life Sciences Group buyback spend peaked at $3.85M in 2010; the latest annual figure is $0.00 in 2025 (100.0% below peak).
The highest annual buyback spend of $3.85M was reported in 2010. The lowest in the available history was $0.00 in 2006.
SELLAS Life Sciences Group Buyback Spend 2025: $0.00
SELLAS Life Sciences Group buyback spend in 2025 was $0.00.
SELLAS Life Sciences Group Buyback Spend 2024: $0.00
SELLAS Life Sciences Group buyback spend in 2024 was $0.00.
SELLAS Life Sciences Group Buyback Spend 2023: $0.00
SELLAS Life Sciences Group buyback spend in 2023 was $0.00.
SELLAS Life Sciences Group Buyback Spend 2022: $0.00
SELLAS Life Sciences Group buyback spend in 2022 was $0.00.
SELLAS Life Sciences Group Buyback Spend 2021: $0.00
SELLAS Life Sciences Group buyback spend in 2021 was $0.00.
See more financial history for SELLAS Life Sciences Group (SLS).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $1.96M | −$1.96M | — | 0.11B | +78.2% | |
| 2024 | $0.00 | $1.56M | −$1.56M | — | 0.06B | +120.3% | |
| 2023 | $0.00 | $1.39M | −$1.39M | — | 0.03B | +43.2% | |
| 2022 | $0.00 | $1.73M | −$1.73M | — | 0.02B | +25.3% | |
| 2021 | $0.00 | $1.01M | −$1.01M | — | 0.02B | +94.1% | |
| 2020 | $0.00 | $578.00K | −$578.00K | — | 0.01B | +211.8% | |
| 2019 | $0.00 | $573.00K | −$573.00K | — | 0.00B | +878.3% | |
| 2018 | $0.00 | $395.00K | −$395.00K | — | 0.00B | +458.8% | |
| 2017 | $0.00 | $3.17M | −$3.17M | — | 0.00B | +147.0% | |
| 2016 | $0.00 | $2.26M | −$2.26M | — | 0.00B | -5.3% | |
| 2015 | $0.00 | $1.93M | −$1.93M | — | 0.00B | -44.2% | |
| 2014 | $0.00 | $5.39M | −$5.39M | — | 0.00B | +32.4% | |
| 2013 | $0.00 | $2.53M | −$2.53M | — | 0.00B | +44.4% | |
| 2012 | $0.00 | $1.39M | −$1.39M | — | 0.00B | +71.9% | |
| 2011 | $0.00 | $3.00M | −$3.00M | — | 0.00B | +97.9% | |
| 2010 | $3.85M | $4.37M | −$519.00K | 0.67% | 0.00B | +13.3% | |
| 2009 | $0.00 | $4.20M | −$4.20M | — | 0.00B | +17.9% | |
| 2008 | $0.00 | $3.82M | −$3.82M | — | 0.00B | +8.5% | |
| 2007 | $0.00 | $0.00 | $0.00 | — | 0.00B | +0.5% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 0.00B | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$0.00
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$0.00
- 2012$0.00
- 2011$0.00
- 2010$3.85M
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$0.00
Buybacks vs stock-based compensation for SELLAS Life Sciences Group (SLS)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for SELLAS Life Sciences Group (SLS)
How SELLAS Life Sciences Group splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as SELLAS Life Sciences Group, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $719.66M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $719.66M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation